Belimumab

Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research[1][2][3][4]. The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.

Product Specifications

CAS Number

[356547-88-1]

Product Name Alternative

LymphoStat B

UNSPSC

12352203

Target

CD20; TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/belimumab.html

Purity

99.40

Solubility

H2O

Smiles

[Belimumab]

Molecular Weight

(144.54 kDa)

References & Citations

[1]Hannah A Blair, et al. Belimumab: A Review in Systemic Lupus Erythematosus. Drugs. 2018 Mar;78 (3) :355-366.|[2]Stohl W, et al. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol. 2012 Jan 9;30 (1) :69-77.|[3]Halpern WG, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci. 2006 Jun;91 (2) :586-99.